Kigali, Rwanda and Accra, Ghana --At today’s session of AHMTEC 2025, Patrick Lukulay, PhD, Bio Usawa’s Chief Operating Officer, had the honor to moderate a session on crosssector collaborations within the vast medical product ecosystem. The session was organized in recognition of the increasing need for medical product innovators to leverage their respective strengths through building productive collaborations and win-win partnerships.

The session brought together CEOs from a broad cross-section of the industry, including medical device, diagnostics, therapeutics and vaccine companies. All agreed to work more closely together to make Africa a major player in the medical product space.

If you are at AHMTEC 2025, be sure to connect with Dr. Lukulay to explore collaboration opportunities — or book a meeting with him via [email protected].

About Bio Usawa Inc.

Bio Usawa is Rwanda's leading biotechnology company dedicated to democratizing access to life-saving biopharmaceuticals across Africa. Founded on the principle that geographic location should not determine healthcare outcomes, the company specializes in developing and manufacturing affordable, high-quality monoclonal antibodies targeting cancer, diabetes complications, infectious diseases, and autoimmune conditions. Bio Usawa's leadership team brings decades of experience from leading global biotech companies and international regulatory agencies.